ClinicalTrials.gg
CompletedNCT04699669Updated Jan 7, 2021

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

A Phase 1 interventional study of CBL-514, placebo and CBL-514, placebo in Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Caliway Biopharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Nov 2018, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.

Read the detailed description

The Phase 1 part of the study was a first-in-human, single ascending dose, double-blind, randomized (except Cohorts 6 to 9 [open-label]) study in healthy subjects to evaluate the safety, tolerability and PK of CBL-514, and to determine the dose levels to be used for the Phase 2a part of the study.

02

Conditions studied

  • Subcutaneous Fat
03

In context

Lead sponsor

Caliway Biopharmaceuticals Co., Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject can participate in the study only if all the following criteria are met:

  1. Male/female aged 18 years to 64 years old (at Screening), inclusive.
  2. >18.5 and \<35 kg/m2 and body weight ≥50 kg at Screening and Day 1.
  3. Has MWC ≥80.0 cm at Screening and Day 1.
  4. Subcutaneous fat thickness of at least 3.00 cm (30.0 mm) by pinch method (measured by calibrated caliper) surrounding the navel at Screening and Day 1.
  5. Voluntarily signs the Form and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will not be eligible to enter the study:

  1. Female subject of who is not willing to commit to an acceptable regimen with her partner from the time of Screening and throughout study participation until 12 weeks after the last study drug dose, or who is currently pregnant or lactating. Male subject who is not willing to commit to an acceptable contraceptive method. Females who have been surgically sterilized (hysterectomy or bilateral oophorectomy) or who are (e.g., defined as at least 50 years with ≥12 months of amenorrhea with a follicle stimulating hormone >40 IU/L) are considered to be of nonchildbearing potential. Subjects who are not of childbearing potential are not required to use contraception.
  2. Subject diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede coagulation or aggregation.
  3. Subject has diabetes or ≥6.5% (48 mmol/mol) or fasting blood sugar ≥7 mmol/L.
  4. Subject has a cardiovascular disease, or shows abnormal findings in at Screening.
  5. Subject with active or prior history of (except for successfully treated non-invasive basal cell carcinoma) or being worked-up for a possible malignancy.
  6. Subject with a history of (HIV)-1, , or infections or subjects with active HIV, hepatitis B, or hepatitis C infections at Screening:

    1. Active HIV infection: positive HIV Ag/Ab combo test;
    2. Active hepatitis B virus (HBV) infection: positive HBV surface antigen (HBsAg). Subjects with negative HBsAg but with positive HBV core antibody with or without positive HBV surface antibody will also be excluded. However, subjects with negative HBsAg, negative HBV core antibody, and positive HBV surface antibody may be included.
    3. Active hepatitis C virus (HCV) infection: positive HCV antibody.
  7. Subject has abnormal skin or local skin conditions, which in the opinion of Investigator is inappropriate to participate in the study, including but not limited to any of the following:

    1. Skin manifestations of a systemic disease,
    2. Any abnormality of the skin or soft tissues of the abdominal wall in the area to be treated,
    3. Skin or superficial tissue that does not lie flat on its own when the subject is in the supine position,
    4. Sensory loss or dysesthesia in the area to be treated,
    5. Evidence of any cause of enlargement in the abdominal area other than localized subcutaneous fat,
    6. Tattoos on the area to be treated.
  8. Subject who has undergone the following procedures:

    1. Previous open or laparoscopic abdominal surgery in the anticipated treatment area,
    2. Cardiac pacemakers or any implantable electrical device,
    3. Metal implants of any type in the area to be treated,
    4. Esthetic procedure to the region to be treated within 6 months before Screening.
  9. Subject is on prescription or over-the-counter weight reduction medication or weight reduction programs within 3 months before Screening.
  10. Subject is undergoing chronic or therapy.
  11. Requiring continual use of the following therapeutic agents during the study:

    S-mephenytoin, terfenadine, buspirone, fexofenadine, breast cancer resistance protein (BCRP) substrates (such as mitoxantrone, methotrexate, topotecan, nitrofurantoin, dipyridamole, statins, etc.), cytochrome P450 3A4 inhibitor, or non-steroidal anti-inflammatory drugs (NSAIDs). If a subject needs to use the above mentioned therapeutic agents during the study for any reason, these therapeutic agents should not be used at least for 48 hours prior to dosing until 24 hours post-dose or the collection of the last PK sample, whichever is later.

  12. Unable to receive topical anesthesia (e.g., history of to lidocaine).
  13. Subjects with known allergies or sensitivities to the study drug and/or .
  14. Subjects with inadequate liver function at Screening defined as , alanine aminotransferase, alkaline phosphatase, total , or gamma-glutamyl transferase >1.5 × . A subject with an elevated liver chemistry test up to 1.5 × ULN at Screening should be evaluated by the Investigator to exclude pre-existing liver disease associated with mild elevation of liver chemistry tests. If the mild elevation is assessed by the Investigator as not clinically significant or related to non-alcoholic fatty liver, the subject may be eligible if the follow-up tests show an unchanged or reducing value from the initial Screening value. A subject with marginally elevated fasting unconjugated serum bilirubin with documented Gilbert's syndrome, and no other cause for the elevated bilirubin on investigation, may be eligible.
  15. Subjects with inadequate renal function, defined as abnormal serum creatinine, and urea >1.5 × ULN or estimated (eGFR) \<60 mL/min/1.73 m2.

    Subjects who are currently on dialysis should be excluded. A subject with serum urea between 1 to 1.5 × ULN at Screening, but an eGFR >60mL/min/1.73 m2 and no other renal risk factors, should be re-tested prior to declaring the subject as eligible. The subject may be eligible if the fasting serum creatinine is not rising nor the eGFR falling, the urinary albumin/creatinine ratio remain \<3 mg/mmol.

  16. Use of other drug or device within 4 weeks prior to Screening.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Other
    Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2

    Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2

    Drug: CBL-514, placebo

  • Other
    Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2

    Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2

    Drug: CBL-514, placebo

  • Other
    Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2

    Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2

    Drug: CBL-514, placebo

  • Other
    Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2

    Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm\^2

    Drug: CBL-514, placebo

  • Other
    Cohort 5: CBL-514 40 mg, 2 mg/cm^2

    Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm\^2

    Drug: CBL-514, placebo

  • Experimental
    Cohort 6: CBL-514 80 mg, 2 mg/cm^2

    CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2

    Drug: CBL-514

  • Experimental
    Cohort 7: CBL-514 160 mg, 2 mg/cm^2

    CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2

    Drug: CBL-514

  • Experimental
    Cohort 8: CBL-514 240 mg, 2 mg/cm^2

    CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2

    Drug: CBL-514

  • Experimental
    Cohort 9: CBL-514 320 mg, 2 mg/cm^2

    CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm\^2

    Drug: CBL-514

Interventions

  • DrugCBL-514, placebo

    One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized. No PK samples will be collected in this cohort.

  • DrugCBL-514, placebo

    One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized.

  • Both sides of the abdominal region will receive CBL-514.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Number of participants experiencing TEAEs and number of individual TEAEs among treatment groups by severity and relationship to investigational product (IP)

    Time frame: Up to 4 weeks after treatment

  2. Number of participants with clinically significant abnormalities in clinical laboratory values

    Clinical laboratory tests include Biochemistry, Hematology, Coagulation and Urinalysis testinjection site reactions.

    Time frame: Up to 2 weeks after treatment

  3. Number of participants with clinically significant abnormalities in vital signs

    Vital signs measurements include temperature, pulse rate, blood pressure, and respiratory rate

    Time frame: Up to 2 weeks after treatment

  4. Number of participants with clinically significant abnormalities in Electrocardiogram (ECG)

    ECG parameters include heart rate, RR interval, PR interval, QT interval, QTc interval, and QRS interval

    Time frame: Up to 2 weeks after treatment

  5. Number of participants with clinically significant abnormalities in physical examination

    Physical examinations include assessment of cardiovascular, respiratory, gastrointestinal, and neurological systems

    Time frame: Up to 2 weeks after treatment

  6. Number of participants with injection site reactions

    Injection site reactions include but not limited to redness, swelling, bruising, tenderness, itching, pain, warmth, discoloration and hardness

    Time frame: Up to 2 weeks after treatment

Secondary outcomes

  1. Assess maximum concentration of CBL-514 in plasma (Cmax)

    To evaluate maximum concentration of CBL-514 in plasma (Cmax) after single dose injection.

    Time frame: Up to 24 hours after treatment

  2. Assess time to Cmax of CBL-514 in plasma (tmax)

    To evaluate time to Cmax of CBL-514 in plasma (tmax) after single dose injection.

    Time frame: Up to 24 hours after treatment

  3. Assess area under the concentration-time curve of CBL-514 in plasma (AUC)

    To evaluate area under the concentration-time curve of CBL-514 in plasma (AUC) after single dose injection.

    Time frame: Up to 24 hours after treatment

  4. Assess terminal rate constant and half-life of CBL-514 in plasma (λz and t1/2)

    To evaluate terminal rate constant and half-life of CBL-514 in plasma (λz and t1/2) after single dose injection.

    Time frame: Up to 24 hours after treatment

  5. Assess apparent clearance and volume of distribution of CBL-514 in plasma (CL/F and Vz/F).

    To evaluate apparent clearance and volume of distribution of CBL-514 in plasma (CL/F and Vz/F) after single dose injection.

    Time frame: Up to 24 hours after treatment

07

Study locations

1 site
  • Investigational site
    Melbourne, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Aug 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2020
First posted
Jan 7, 2021
StartActual
Nov 27, 2018
Primary completionActual
Aug 20, 2019
CompletionActual
Aug 20, 2019
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04699669
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Nov 27, 2018
Primary completion
Aug 20, 2019
Completion
Aug 20, 2019
Last update
Jan 7, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBL-514

Start the discussion